|
시장보고서
상품코드
2050967
유전성 혈관부종 시장 : 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별Hereditary Angioedema Market By Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
유전성 혈관부종 시장은 2026년에 34억 4,000만 달러로 추정되고, 2033년까지 66억 1,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 9.8%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 34억 4,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 9.80% | 2033년 시장 규모 예측 : | 66억 1,000만 달러 |
유전성 혈관성 부종은 심한 피하 또는 점막하 부종이 반복적으로 발생하는 것이 특징인 희귀한 유전성 질환입니다. 증상으로는 손, 발, 사지, 얼굴, 소화관, 호흡기 부종 발작이 있습니다. 이러한 발작은 보체 및 선천성 시스템의 특정 부분을 조절하는 역할을 하는 혈청 단백질인 C1 억제제의 수준 감소 또는 기능 저하로 인해 발생합니다. 유전성 혈관성 부종 환자는 평균적으로 4주에 한 번 이상 부종 발작을 경험하며, 증상 관리를 위해 의료적 개입이 필요한 것이 일반적입니다. 전 세계 유병률 증가와 사용 가능한 치료 옵션에 대한 인식이 높아짐에 따라 유전성 혈관성 부종 시장의 성장을 가속할 수 있습니다.
시장 역학
치료법 연구 발전, 전 세계 HAE 유병률 증가, FDA 승인 약물의 가용성, 질병에 대한 인식 증가 등이 유전성 혈관부종 시장의 성장을 견인할 것으로 보입니다. 그러나 HAE 치료에 따른 높은 비용과 개발도상국에서의 낮은 인식이 시장 성장을 저해할 수 있습니다. 피하 투여형 C1-INH 제제 및 경구용 치료제 개발은 시장 진출기업에게 새로운 기회를 제공합니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계 유전성 혈관성 부종(HAE) 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 세계 유전성 혈관 부종 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 유전성 혈관성 부종 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 유전성 혈관부종 시장 : 유형별, 2021년-2033년
제5장 유전성 혈관부종 시장 : 약제 클래스별, 2021년-2033년
제6장 유전성 혈관부종 시장 : 투여 경로별, 2021년-2033년
제7장 유전성 혈관부종 시장 : 유통 채널별, 2021년-2033년
제8장 유전성 혈관부종 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고 문헌 및 조사 방법
LSH 26.06.15Hereditary Angioedema Market is estimated to be valued at USD 3.44 Bn in 2026 and is expected to reach USD 6.61 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.44 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 6.61 Bn |
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of intense subcutaneous or submucosal edema. Symptoms include episodes of swelling in the hands, feet, limbs, face, intestinal tract and airway. The episodes are caused by decreased levels or functioning of C1 inhibitor, which is a serum protein responsible for regulating certain parts of the complement and fibrinolytic systems. Patients with hereditary angioedema experience episodes of edema at least once every 4 weeks on average and commonly require medical intervention for symptom management. Increasing prevalence of disease globally and rising awareness about available treatment options can drive the hereditary angioedema market growth.
Market Dynamics
Increasing research into treatment alternatives, rising prevalence of HAE globally, availability of FDA approved drugs and growing awareness about the disease can drive the hereditary angioedema market growth. However, high costs associated with HAE therapies and lack of awareness in developing countries can hamper the market growth. Development of subcutaneous C1-INH products and oral treatments offers new opportunities for the market players.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hereditary angioedema market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market.
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2021 - 2033)
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- By Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Bradykinin Receptor
- Attenuated Androgens
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Subcutaneous
- Intravenous
- Oral
- By Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE N.V.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Hereditary Angioedema Market, By Type
- Hereditary Angioedema Market, By Drug Class
- Hereditary Angioedema Market, By Route of Administration
- Hereditary Angioedema Market, By Distribution Channel
- Hereditary Angioedema Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Hereditary Angioedema Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hereditary Angioedema Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hereditary Angioedema Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Hereditary Angioedema Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- C1 Esterase Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bradykinin Receptor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Attenuated Androgens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Hereditary Angioedema Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Hereditary Angioedema Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Hereditary Angioedema Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026,2028 & 2033, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orchard Therapeutics plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pharming Group N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioCryst Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Attune Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arrowhead Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Adverum Biotechnologies, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- KalVista Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CENTOGENE N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
